Results 21 to 30 of about 19,727 (209)

Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis. [PDF]

PLoS ONE, 2018
Thailand is encountering challenges to introduce the high-cost sofosbuvir for chronic hepatitis C treatment as part of the Universal Health Care's benefit package.
Waranya Rattanavipapong, Thunyarat Anothaisintawee, Yot Teerawattananon   +2 more
doaj   +1 more source

Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study [PDF]

, 2018
AIM: To evaluate waiting list (WL) registration and liver transplantation (LT) rates in patients with hepatitis C virus (HCV)-related cirrhosis since the introduction of direct-acting antivirals (DAAs).
Angeli, Paolo, Burra, Patrizia, Cillo, Umberto, Ferrarese, Alberto, Gambato, Martina, Germani, Giacomo, Russo, Francesco Paolo, Senzolo, Marco, Shalaby, Sarah, Zanetto, Alberto, Zanus, Giacomo   +10 more
core   +1 more source

Recurrent hyperkalemia in patients with chronic kidney disease and hepatitis C treated with direct antiviral agents

BMC Infectious Diseases, 2019
Background Sofosbuvir is the keystone of direct antiviral agents for the chronic hepatitis C (CHC). The safety of sofosbuvir in patients with stage 4–5 chronic kidney disease (CKD) needs further observation in real world.
Taotao Yan, Jiuping Wang, Juan Li, Shan Fu, Yi Chen, Chunhua Hu, Rou Zhang, Zhen Tian, Fahui Zhao, Jun Dong, Jinfeng Liu, Yuan Yang, Tianyan Chen, Yingren Zhao, Yingli He   +14 more
doaj   +1 more source

Diagnostic approach to elucidate the efficacy and side effects of direct-acting antivirals in HCV infected patients

Journal of Infection in Developing Countries, 2021
Introduction: The conventional interferon therapy of hepatitis C virus has been substituted substantially with sofosbuvir and daclatasvir due to constraints in efficacy and tolerability.
Sonia Younas, Hamid Mukhtar, Umar Farooq Gohar, Abdullah Alsrhani, Badr Alzahrani, Kashaf Junaid, Muhammad Usman Qamar, Hasan Ejaz   +7 more
doaj   +1 more source

Timing for treatment of HCV recurrence after liver transplantation: the earlier the better. [PDF]

, 2016
HCV is the leading cause of death from liver disease and is the most common indication for a liver transplantation. Although HCV is a widespread health problem, disease management is particularly challenging in several key subpopulations, including liver
Burra, Patrizia, Russo, Francesco Paolo, Zanetto, A   +2 more
core   +1 more source

Medicament testing on acupuncture points as a non-invasive diagnostic tool for determining the daily doses of sofosbuvir in patients with chronic hepatitis C virus infection

Future Journal of Pharmaceutical Sciences, 2023
Background Acupuncture points are known for their unique bioelectric properties. Medication testing at acupuncture points has not previously been used to determine the daily doses of sofosbuvir in patients with chronic hepatitis C virus infection ...
Naylya Djumaeva, Gulnara Akhundjanova, Leyla Djumaeva, Dilbar Urunova   +3 more
doaj   +1 more source

Activation of Tenofovir Alafenamide and Sofosbuvir in the Human Lung and Its Implications in the Development of Nucleoside/Nucleotide Prodrugs for Treating SARS-CoV-2 Pulmonary Infection

Pharmaceutics, 2021
ProTide technology is a powerful tool for the design of nucleoside/nucleotide analog prodrugs. ProTide prodrug design improves cell permeability and enhances intracellular activation.
Jiapeng Li, Shuhan Liu, Jian Shi, Hao-Jie Zhu   +3 more
doaj   +1 more source

Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C. [PDF]

, 2015
Sofosbuvir and simeprevir are used for the treatment of chronic hepatitis C (HCV) genotype 1. Both drugs have been well-tolerated, with diarrhea noted in 6% cases with sofosbuvir, 16% with sofosbuvir plus simeprevir, and 0% with simeprevir.
Jakab, Simona, Lim, Joseph K, Mitchell, Kisha A, Oikonomou, Ioannis, Sarkar, Souvik   +4 more
core   +1 more source

Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo. [PDF]

PLoS Neglected Tropical Diseases, 2019
Yellow fever virus (YFV) is a member of the Flaviviridae family. In Brazil, yellow fever (YF) cases have increased dramatically in sylvatic areas neighboring urban zones in the last few years. Because of the high lethality rates associated with infection
Caroline S de Freitas, Luiza M Higa, Carolina Q Sacramento, André C Ferreira, Patrícia A Reis, Rodrigo Delvecchio, Fabio L Monteiro, Giselle Barbosa-Lima, Harrison James Westgarth, Yasmine Rangel Vieira, Mayara Mattos, Natasha Rocha, Lucas Villas Bôas Hoelz, Rennan Papaleo Paes Leme, Mônica M Bastos, Gisele Olinto L Rodrigues, Carla Elizabeth M Lopes, Celso Martins Queiroz-Junior, Cristiano X Lima, Vivian V Costa, Mauro M Teixeira, Fernando A Bozza, Patrícia T Bozza, Nubia Boechat, Amilcar Tanuri, Thiago Moreno L Souza   +25 more
doaj   +1 more source

Clinical-evolutional particularities of the cryoglobulinemic vasculitis in the case of a patient diagnosed with hepatitis C virus in the predialitic phase [PDF]

, 2018
Hepatitis C virus (HCV) represents a fundamental issue for public health, with long term evolution and the gradual appearance of several complications and associated pathologies.
Boldeanu, Lidia, Boldeanu, Mihail V., Caragea, Daniel C., Ciurea, Marius E., Ciurea, Tudorel, Forțofoiu, Maria, Forțofoiu, Mircea C., Popescu-Drigă, Mircea, Pădureanu, Vlad, Rogoveanu, Ion, Streba, Costin, Săndulescu, Larisa, Vere, Cristin C.   +12 more
core   +3 more sources